Loteprednol Etabonate Now Available for Postoperative Ocular Pain
Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% has been made available by Bausch + Lomb for the treatment of postoperative inflammation and pain following ocular surgery.
All articles by Diana Ernst, RPh
Lotemax SM Approved for Post-Op Inflammation, Pain Following Ocular Surgery
The Food and Drug Administration (FDA) has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery.
Chronic Low Back Pain Study Results Indicate Benefit With Tanezumab
Tanezumab, an investigational subcutaneously-administered, non-opioid treatment, may benefit patients with moderate to severe chronic low back pain (CLBP), according to top-line results from a Phase 3 study.
Next post in Low Back Pain
